louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06088498: App for Reducing Cravings to Smoke
Official title: Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Smoking
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2023-10-18
Enrollment: 3600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.

Detailed description: The aims of the study are: (1) to update a recently developed study-related smartphone application to reduce cravings to smoke to be an engaging, user-friendly treatment tool, and verify user satisfaction; and (2) to test in a randomized controlled trial the efficacy of the app as an adjunct to quitline smoking cessation treatment in improving smoking abstinence compared to the quitline only.

Eligibility criteria: Inclusion Criteria:

* \>18 years of age
* Daily smokers that have quit smoking within the past 3 months (Aim 1) or currently smoking ≥ 3 cigarettes per day for the past year (Aim 2)
* Functioning telephone number
* Owns a smart phone capable of supporting AR and willing to download the app
* Can speak, read and write in English

Exclusion Criteria:

* Has another household member already enrolled in the study

Primary outcomes:
measure: System Usability Scale (Aim 1)
timeFrame: At 1 Week
measure: Tobacco Abstinence (Aim 2)
timeFrame: At 6 Months
Secondary outcomes:
measure: User Satisfaction (Aim 1)
timeFrame: At 1 Week
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
Study officials:
affiliation: Moffitt Cancer Center
name: Christine Vinci, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07019298: Success of Endodontic Treatment With Different Obturation Techniques and Sealer Cements
Official title: Evaluation of the Success Rate of Endodontic Treatment Using Different Obturation Techniques and Root Canal Sealer Cements: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pulpitis
Periapical Lesions
Periapical Periodontitis
Periapical Pathology
Keywords: Endodontics
Endodontic Sealer
Calcium Silicate-Based Sealer
Ah Plus
Lead sponsor: University of Siena
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 270
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study aims to compare the radiographic success of endodontic treatment using Orstavik's criteria between two sealers: AH Plus (Dentsply DeTrey, Konstanz, Germany) and Neosealer Flo (Avalon Biomed, Bradenton, Florida, USA), as well as between two obturation techniques: continuous wave and single cone. The study includes 270 patients, with a minimum follow-up period of 6 months. Clinical and radiographic variables will be assessed, including quality of obturation, lesion healing, and restoration. The study seeks to determine if the use of bioceramic sealer is effective regardless of the obturation technique used, highlighting the importance of clinical follow-up to evaluate endodontic treatment success.


Eligibility criteria: Inclusion Criteria:

Patients aged 18 years and older. Teeth with a diagnosis of pulpal necrosis or irreversible pulpitis. Informed consent provided for data usage.

Exclusion Criteria:

* Patients with systemic conditions that may impair healing (e.g., uncontrolled diabetes, immunosuppression).
* Teeth with root fractures, resorption, or open apices.
* Incomplete clinical or radiographic records.
* Cases with poor-quality radiographs or lack of standardization for evaluation

Primary outcomes:
measure: Radiographic Success Based on Periapical Index (PAI) Criteria
timeFrame: Minimum 6 months after root canal treatment
Secondary outcomes:
measure: Clinical Success Based on Absence of Symptoms
timeFrame: Minimum 6 months after treatment
measure: Radiographic Success Based on CBCT Evaluation
timeFrame: Minimum 6 months after treatment
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Universidad Rey Juan Carlos
Study officials:
References:
Clinical trial NCT02235298: Dapagliflozin Effects on Epicardial Fat
Official title: Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes
Keywords: epicardial fat
diabetes
dapagliflozin
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2014-09-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes, as defined by ADA criteria
* HbA1c \< 8% measured at least 1 week prior to the study
* BMI ≥27 kg/m2
* Pre-treatment with Metformin as monotherapy
* Age \> 18 and \< 65 years old
* Normal and stable hemodynamic status

Exclusion Criteria:

* Known contra-indications to Farxiga, in accordance with risks and safety information included in the latest updated Prescribing Information
* Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria
* Insulin dependent or treated type 2 diabetes
* Current use of other SGLT2 inhibitors, Glucagon Like Peptide -1 (GLP- 1) analogs or Dipeptidyl Peptidase 4 (DPP4) inhibitors
* Glomerular Filtration Rate (GFR) \< 60 mL/min/1.73 m2
* Signs or symptoms of hypovolemia
* Patients with poor glycemic control (HbA1c ≥ 8%) will be excluded to maximize long-term patient retention without need
* History of diabetes ketoacidosis
* Patients with active bladder cancer or with a prior history of bladder cancer
* Acute or chronic infective, including genital mycotic infections
* Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure
* Clinical or laboratory evidences of chronic active liver diseases
* Acute or chronic infective diseases
* Cancer or chemotherapy
* Current use of systemic corticosteroids or in the 3 months prior this study
* Known or suspected allergy to Dapagliflozin, excipients, or related products
* Pregnant, breast-feeding or the intention of becoming pregnant
* Females of childbearing potential who are not using adequate contraceptive methods

Primary outcomes:
measure: Epicardial Fat Thickness
timeFrame: At Baseline, 12 weeks, 24 weeks
Secondary outcomes:
measure: Left Ventricular Mass (LVM)
timeFrame: At Baseline, Week 12 and Week 24
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Gianluca Iacobellis, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05716698: Health Evaluation of Mushrooms withVitamin D2
Official title: Health Evaluation of Mushrooms withVitamin D2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Taipei Medical University
Sponsor class: OTHER
First posted: 2023-02-08
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Although Taiwan has plenty of sunshine, the intake of vitamin D and the concentration of 25(OH)D in the blood are low. Ingestion of mushrooms and extracts rich in D2 can increase the nutritional source of vitamin D. The purpose of this study is to evaluate the intake of D2 mushrooms and extracts in humans to achieve the effective concentration of 25(OH)D in the serum and recommendations for health improvement.

Detailed description: The subjects were divided into 3 groups: no mushroom intervention, intervention with D2 10ug Pleurotus citrinopileatus after bio-optics optimization (low dose group) or intervention with D2 100ug Pleurotus citrinopileatus after bio-optics optimization (high dose group). The low-dose group took D2 10ug per day, and the high-dose group received D2 100ug per day for a total of 4 weeks.

Eligibility criteria: Inclusion Criteria:

1. Healthy human

Exclusion Criteria:

1. Any acute disease, such as infection, stroke, myocardial infarction or major surgery within three months, upper or lower gastrointestinal bleeding, blood pressure, and poor blood sugar control will be excluded.
2. Chronic diseases, such as malignant tumors, infection with human immunodeficiency virus (HIV) and related diseases, liver cirrhosis, or those with liver function exceeding 3 times the normal value (more than 120 IU/L), renal function (Cr) more than 2.5 mg /dl, chronic anemia (Hb \<9 g/dl), metabolic diseases except diabetes (such as thyroid/parathyroid dysfunction), and those who have undergone abdominal surgery to cause intestinal sticking are excluded.
3. Women who are pregnant or breastfeeding will be excluded.
4. Those who use steroids, supplements with vitamin D-containing dietary supplements and hormones will be excluded.
5. Those with blood 25(OH)D concentration \> 30 ng/ml will be excluded.
6. Those who are unwilling to fill out the consent form and refuse the questionnaire survey.

Primary outcomes:
measure: Change from baseline in 25OHD at week 4
timeFrame: Baseline and week 4
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University
Study officials:
affiliation: Office of Human Research, Taipei Medical University
name: Chih-Han Lin, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00881998: Study of Two Surgical Approaches for Total Hip Arthroplasty
Official title: Prospective, Randomized Study of Two Surgical Approaches for Total Hip Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Total Hip Arthroplasty
Keywords: Evaluate early functional outcomes of two anterior approaches to total hip arthroplasty
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2009-04-16
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: A prospective, comparative, randomized single surgeon study comparing minimally invasive total hip arthroplasty (MIS) via anterior approach to conventional total hip arthroplasty via anterolateral transgluteal approach.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with osteoarthritis of the hip and have decided to undergo total hip arthroplasty
* Patients willing to sign the consent form

Exclusion Criteria:

* Patient is unwilling to sign the consent form
* Patient is involved in another study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Institute Orthorpaedics
state: Pennsylvania
Study officials:
affiliation: Rothman Institute Orthopaedics
name: William Hozack, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00689598: Spironolactone for Paroxysmal Atrial Fibrillation
Official title: Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation, spironolactone
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2008-06-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

Detailed description: To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.

Eligibility criteria: Inclusion criteria:

1. 18 to 80 Y/O,
2. Paroxysmal AF.

Exclusion criteria:

1. GPT\>100 IU/L or tota bilirubin \>2 mg/dl;
2. Creatinine \> 2 mg/dl;
3. Serum potassium \>= 5 mM;
4. Serum sodium \<=130 mM;
5. Uric acid \> 10 mg/dl。

Primary outcomes:
measure: time to a first electrocardiographically confirmed AF
timeFrame: 3 months
Secondary outcomes:
measure: 1. Response rate: Improvement of any symptom scores and/or SF36 scores more than 50 % (compared with re-randomization scores) 2. Difference of mean episodes of documented AF between the spironolactone and placebo groups.
timeFrame: 3 months
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung General Hospital
Study officials:
affiliation: TCVGH
name: Tsu-Juey Wu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00367198: Protein Supplementation in Dialysis Patients
Official title: Protein Supplementation in Dialysis Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: End Stage Renal Disease
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2006-08-22
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The mortality rate in chronic hemodialysis (CHD) patients remains excessively high and approaches 21% per year. Among the many factors that adversely affects patient outcome is uremic malnutrition, a unique form of deranged nutritional status. It is associated with increased hospitalization and death risk in CHD patients. Several measures have been identified to prevent uremic malnutrition in CHD patients, including efforts to optimize dialysis regimen and dietary protein and energy intake. A large number of CHD patients suffer from uremic malnutrition in spite of these aggressive measures. The inevitable protein catabolic effects of the hemodialysis procedure are important factors leading to increased prevalence of uremic malnutrition. Preliminary data suggest that oral nutritional supplementation administered during the hemodialysis procedure counteracts these protein catabolic effects and leads to net protein anabolism in the acute setting. In this proposal, we hypothesize that Pro-Stat, a high nitrogen, enzyme-hydrolyzed, tryptophan-fortified, collagen protein supplement will reverse the net protein catabolism observed during hemodialysis procedure.


Eligibility criteria: Inclusion criteria:

* On hemodialysis for more than 3 months, on a thrice weekly hemodialysis program.
* Adequately dialyzed (Kt/V \> 1.2).
* Age 18-75

Exclusion criteria:

* Pregnant women.
* Severe unstable underlying disease besides commonly associated with end stage renal disease. Cardiac patients that are stable will be included.
* Patients hospitalized within the last month prior to the study.
* Patients with malfunctioning arterial-venous access \[recirculation and/or blood flow \< 500 ml/min for an arterial-venous graft (AVG) or \<400 ml/min for an arterial-venous fistula (AVF)\] Patients receiving steroids and/or other immunosuppressive agents.

Primary outcomes:
measure: net muscle protein balance
timeFrame: 10 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Alp Ikizler, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2.
Clinical trial NCT01698398: The Increase Study. Effect of Incremental Versus Fixed Pump on Peak Oxygen Consumption in Heart Failure Patients Supported With a Continuous Flow Left Venticular Assist Device
Official title: The Increase Study. Effect of Incremental Versus Fixed Pump on Peak Oxygen Consumption in Heart Failure Patients Supported With a Continuous Flow Left Venticular Assist Device.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure.
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2012-10-03
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED

Brief summary: The purpose of the study is to examine the relationship between working capacity (peak oxygen consumption) and pump speed of continuous flow left ventricular assist devices (CF-LVADs)in heart failure patients. The hypothesis is that it is possible to increase peak oxygen consumption by incrementally increasing CF-LVAD pumpspeed during exercise.

The study population will consist of severe heart failure patients with CF-LVADs treated at The Heart Centre of Copenhagen University Hospital Rigshospitalet.


Eligibility criteria: Inclusion Criteria:

* HeartMate II patients who underwent surgery and follow-up at The Heart Centre of Rigshospitalet.
* Heart failure in stable phase without the need for intravenous inotropic therapy.
* Ischemic and non-ischemic cardiomyopathy.

Exclusion Criteria:

* Severe aortic insufficiency.

Primary outcomes:
measure: Peak oxygen consumption.
timeFrame: Day 1
Secondary outcomes:
measure: Working capacity.
timeFrame: Day 1
Other outcomes:
measure: Exercise time (minutes), anerobic threshold.
timeFrame: Day 1
Locations:
city: Copenhagen.
country: Denmark
facility: Department of Cardiology, Copenhagen University Hospital, Rigshospitalet.
Study officials:
References:
citation: Jung MH, Hansen PB, Sander K, Olsen PS, Rossing K, Boesgaard S, Russell SD, Gustafsson F. Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. Eur J Heart Fail. 2014 Apr;16(4):403-8. doi: 10.1002/ejhf.52.
Clinical trial NCT04373798: C-reactive Protein Levels Among Individuals With COVID-19
Official title: Triage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19: A Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronavirus Infection
Lead sponsor: Frederiksberg University Hospital
Sponsor class: OTHER
First posted: 2020-05-04
Enrollment: 1006
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals who are COVID-19 positive at the check point test.

Brief summary: The primary objective of this multi-center study is to clarify the value of a CRP measurement for triage of patients initially presenting with light symptoms of the COVID-19 infection.

Current recommendations of management of COVID-19 include large-scale tests for virus. Such tests reveal whether an individual is infected with the virus, however, the demonstration of virus per se has no prognostic value for the ensuing course of the COVID-19 disease. Publications of possible treatments strategies increase exponentially, while evidence of triage of the affected individuals is mainly based on the level of pulmonary affection as measured by the Oxygen saturation.

To inform decision making for which patients are to be hospitalized due to risk of developing more severe affection, this study addresses the question, whether triage may be performed with the aid of a simple CRP measurement.


Eligibility criteria: Inclusion Criteria:

1. A test for COVID-19 taken at the check point
2. Signed, informed consent for blood test to be drawn for the Biobank

Exclusion Criteria:

1. Former admission to hospital for COVID-19
2. Direct admission from check point.

Primary outcomes:
measure: Hospitalisation
timeFrame: within 28 days
Secondary outcomes:
measure: Death
timeFrame: within 28 days
measure: Transfer to Intensive Care Unit
timeFrame: within 28 days
measure: Oxygen treatment during hospitalisation
timeFrame: within 28 days
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: The Parker Institute, Frederiksberg Hospital
Study officials:
affiliation: The Parker Institute
name: Henning Bliddal, DMSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05931198: Several Studys Showed That Upper Limb Amputated Patients Are Able to Experience the Illusion of the Rubber Hand Whith Prosthesis: We Want to go Futher by Comparing the Strength of the Incorporation According to the Type of Prosthesis Using the Illusion of the Rubber Hand With Prothesis
Official title: Incorporation de prothèses Chez Les Patients amputés de Membre supérieur à l'IRMA
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Appropriate Affect
Lead sponsor: Institut Robert Merle d'aubigné
Sponsor class: OTHER
First posted: 2023-07-05
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The goal of this observational study is to compare the strength of the incorporation according to the type of prosthesis (aesthetic, mechanical, myoelectric) with the experience the illusion of the rubber hand. The investigators will replace is the rubber by the patient's prothesis. The population will be people with upper arm amputation above the hand and they will be their own comparation.

Participants will do the the experience the illusion of the rubber hand in asynchronic and synchronic way and to answer questionnaries.


Eligibility criteria: Inclusion Criteria:

* At least one upper limb amputation
* Informed and consented to participate to the study

Exclusion Criteria:

* having a history of severe neurological, visual or musculoskeletal impairments (other than the loss of a limb)
* with severe serious psychiatric disorders (e.g. schizophrenia)
* having problems understanding French in order to guarantee a good understanding of the questionnaires
* under guardianship or curatorship

Primary outcomes:
measure: Proprioceptive drift
timeFrame: Immediately after the intervention
Secondary outcomes:
measure: Appropriate affect
timeFrame: Immediately after the intervention
measure: Influence of patient's characteristic
timeFrame: During the patient's inclusion / Baseline
Other outcomes:
Locations:
city: Valenton
country: France
facility: Institut Robert Merle d'Aubigné
Study officials:
References:
citation: Botvinick M, Cohen J. Rubber hands 'feel' touch that eyes see. Nature. 1998 Feb 19;391(6669):756. doi: 10.1038/35784. No abstract available.
citation: Ehrsson HH, Rosen B, Stockselius A, Ragno C, Kohler P, Lundborg G. Upper limb amputees can be induced to experience a rubber hand as their own. Brain. 2008 Dec;131(Pt 12):3443-52. doi: 10.1093/brain/awn297. Epub 2008 Dec 11.